The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Variables with the corresponding odds ratios and confidence intervals are shown in the figure.SARS-CoV-2, acute respiratory syndrome coronavirus 2; BP, bullous pemphigoid; COVID-19, coronavirus ...

A recent case report explains how epitope spread may cause immune checkpoint inhibitor (ICI)–associated bullous pemphigoid (BP). A separate research letter spotlights cases of partial ...